Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Myelodysplastic Syndromes 3Recurrence 2Neoplasms 2Leukemia 2Rubinstein-Taybi Syndrome 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1Hodgkin Disease 1Carcinoma, Transitional Cell 1Bronchiolitis Obliterans Syndrome 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × mocetinostat × Clear all
NCT00323934 2015-01-08

Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Mirati Therapeutics Inc.

Phase 1 Completed
42 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡